DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

BACKGROUND: Patients with advanced T cell lymphomas (TCLs) have limited therapeutic options and poor outcomes in part because their TCLs evade apoptosis through upregulation of anti-apoptotic Bcl-2 proteins. Subsets of TCL cell lines, patient-derived xenografts (PDXs), and primary patient samples de...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Hematol Oncol
Auteurs principaux: He, Yonghan, Koch, Raphael, Budamagunta, Vivekananda, Zhang, Peiyi, Zhang, Xuan, Khan, Sajid, Thummuri, Dinesh, Ortiz, Yuma T., Zhang, Xin, Lv, Dongwen, Wiegand, Janet S., Li, Wen, Palmer, Adam C., Zheng, Guangrong, Weinstock, David M., Zhou, Daohong
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7364785/
https://ncbi.nlm.nih.gov/pubmed/32677976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00928-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires